113 related articles for article (PubMed ID: 21159885)
21. [Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy].
Ying J; Yao DH; Ren XM
Zhonghua Nan Ke Xue; 2003 Jun; 9(3):191-2, 196. PubMed ID: 12861832
[TBL] [Abstract][Full Text] [Related]
22. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
24. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
25. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
26. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
27. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
[TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
Garzotto M; Wajsman Z
J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
[TBL] [Abstract][Full Text] [Related]
29. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.
Sgambato A; De Paola B; Migaldi M; Di Salvatore M; Rettino A; Rossi G; Faraglia B; Boninsegna A; Maiorana A; Cittadini A
J Cell Physiol; 2007 Nov; 213(2):528-39. PubMed ID: 17516554
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.
Fuzio P; Lucarelli G; Perlino E; Battaglia M; Bettocchi C; Selvaggi FP; Ditonno P
Oncol Rep; 2009 Aug; 22(2):327-35. PubMed ID: 19578773
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
[TBL] [Abstract][Full Text] [Related]
32. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation status of Fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomes.
Matsumura Y; Shimada K; Tanaka N; Fujimoto K; Hirao Y; Konishi N
Pathobiology; 2009; 76(6):293-302. PubMed ID: 19955841
[TBL] [Abstract][Full Text] [Related]
34. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue.
Valdman A; Jaraj SJ; Compérat E; Charlotte F; Roupret M; Pisa P; Egevad L
APMIS; 2010 May; 118(5):360-5. PubMed ID: 20477811
[TBL] [Abstract][Full Text] [Related]
35. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
36. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
37. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
38. Androgen regulation of micro-RNAs in prostate cancer.
Waltering KK; Porkka KP; Jalava SE; Urbanucci A; Kohonen PJ; Latonen LM; Kallioniemi OP; Jenster G; Visakorpi T
Prostate; 2011 May; 71(6):604-14. PubMed ID: 20945501
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
